

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

RELEVANT EVENT

Following the Relevant Event, dated 7 March 2019, where it was reported that Grifols and Shanghai RAAS Blood Products Co. Ltd. ("**SR**") had signed an "Agreement for Asset Purchase by Share Issuance", as well as an "Exclusive Strategic Alliance Agreement", though the transaction was subject to the approval of the regulatory authorities of both the People's Republic of China and the United States of America, Grifols reports:

- That on 30 September 2019, Grifols obtained the authorization from the Committee on Foreign Investment in the United States (CFIUS) to complete the transaction; and
- That on 13 November 2019, Shanghai RAAS Blood Products Co. Ltd., has obtained the authorization from the Chinese Securities Regulatory Commission (CRSC) to complete the transaction.

Since the transaction has been approved by the relevant governmental authorities, which have jurisdiction over it, the closing is expected to take place during this calendar year 2019.

By means of this transaction, Grifols will acquire 26.2% voting and economic rights in SR. Grifols will contribute 45% economic rights in its US subsidiary Grifols Diagnostic Solutions Inc. ("**GDS**") that is wholly owned by Grifols and 40% voting rights in GDS and, therefore, Grifols will continue to hold 55% economic rights and 60% voting rights in GDS.

In Barcelona, on 13 November 2019

Nuria Martín Barnés
Secretary to the Board of Directors